Related Experiment Videos
[Bone marrow transplantation. Overview and personal results]
1Klinik und Poliklinik für Knochenmarktransplantation, Universitätsklinikums, Essen.
Zentralblatt Fur Chirurgie
|January 1, 1992
Summary
Allogeneic bone marrow transplantation is a key treatment for severe anemias and leukemias, offering 50-80% survival rates. Early intervention improves outcomes, though risks like toxicity and graft-versus-host disease persist.
Area of Science:
- Hematology
- Transplantation Immunology
Background:
- Allogeneic bone marrow transplantation (BMT) is a critical therapy for severe hematologic disorders.
- Indications include severe aplastic anemia, severe combined immunodeficiency, and various leukemias.
Purpose of the Study:
- To outline the primary indications and outcomes of allogeneic bone marrow transplantation.
- To discuss the challenges and donor selection criteria in BMT.
- To briefly mention autologous transplantations.
Main Methods:
- Review of established indications for allogeneic bone marrow transplantation.
- Analysis of survival rates based on disease stage and risk.
- Discussion of complications and donor sourcing (related vs. unrelated).
Main Results:
- Survival rates in standard risk cases range from 50% to 80%.
- Disease stage significantly impacts disease-free survival probability.
- Therapy-related organ toxicity, graft rejection, graft-versus-host disease, and infection are major complications.
Conclusions:
- Allogeneic bone marrow transplantation is effective for specific severe hematologic conditions, with outcomes dependent on disease stage.
- Early transplantation is recommended over treatment for advanced disease.
- While related donors are standard, unrelated donor research and autologous transplantations are ongoing.